Background. Annual vaccination for healthcare workers and other high-risk groups is the mainstay of the public health strategy to combat influenza. Inactivated influenza vaccines confer protection by inducing neutralizing antibodies efficiently against homologous and closely matched virus strains. In the absence of neutralizing antibodies, cross-reactive T cells have been shown to limit disease severity. However, animal studies and a study in immunocompromised children suggested that repeated vaccination hampers CD8 + T cells. Yet the impact of repeated annual influenza vaccination on both cross-reactive CD4 + and CD8 + T cells has not been explored, particularly in healthy adults.
Annual influenza vaccination is the most effective strategy available to combat seasonal influenza and is routinely recommended in many countries for children, older adults, healthcare workers (HCWs), and other high-risk groups [1, 2] . However, emerging data suggest that repeated vaccination hinders the influenza-specific CD8 + T-cell immunity, a potential double-edged sword effect. Annual vaccination may prevent natural infection that boosts these cross-reactive T cells, thus potentially increasing susceptibility to influenza illness in the event of a vaccine mismatch or a pandemic [3] . In light of recent evidence in humans for a protective role of CD8 + T cells in the absence of neutralizing antibodies, this leads to the question of the impact of vaccination history on immunity to influenza and the immunological evidence base for the policy of repeated annual vaccination.
Current inactivated influenza vaccines mediate protection by inducing strain-specific neutralizing antibodies predominantly against hemagglutinin (HA), the major surface glycoprotein. Occasionally, the emergence of new influenza virus with antigenic differences in the HA protein results in a mismatch between the vaccine and circulating strains, leading to decreased vaccine efficacy. This necessitates annual updating of influenza vaccine composition and the need for annual vaccination of high-risk groups. In the absence of strain-specific anti-HA neutralizing antibodies, recent work has demonstrated a protective effect of preexisting influenza-specific interferon γ (IFN-γ)-secreting CD4 + [4] and CD8 + [5, 6] memory T cells recognizing conserved internal viral epitopes [7] . These memory T cells are long lived and may provide long-lasting protection from heterosubtypic influenza viruses [8] . Although multiple studies have reported an induction of influenza-specific CD4 + T cells after a single vaccination [9] [10] [11] [12] , less is known about the impact of repeated vaccination on memory CD4 + T cells. Furthermore, 1 study reported a hampering of the cross-reactive CD8 + T cells in immunocompromised children who had received multiple annual vaccinations [13] . Yet the critical question of whether repeated annual influenza vaccination impacts upon both cross-protective CD4 + and CD8 + T cells remains unanswered, particularly in healthy adults.
To address this key question, we conducted a 5-year longitudinal cohort study in HCWs vaccinated with an adjuvanted monovalent H1N1 pandemic 2009 (H1N1pdm09) vaccine. We compared immune responses between those who subsequently received seasonal vaccine every year (repeated vaccination) and those who did not (single vaccination) to test the hypothesis that repeated vaccination adversely impacts on long-term cross-protective T-cell responses. This study is the first to explore both strain-specific and cross-reactive T-cell responses, as well as antibodies, after repeated versus single vaccination, and is the longest follow-up study in the post-H1N1pdm09 era. Our findings have important implications for public vaccination policy.
MATERIALS AND METHODS

Study Population
Healthcare workers at the Haukeland University Hospital were recruited into an open-label 5-year extension of the single-arm clinical trial in 2009, which had ethical and regulatory approval (www.clinicaltrials.gov, NCT01003288). All participants provided written informed consent before inclusion and were vaccinated with a single dose of the AS03-adjuvanted monovalent split A(H1N1)pdm09 virus vaccine. The inclusion/exclusion criteria have been published [14] . Healthcare workers were followed up through 2010-2013 and categorized into either the single (no further vaccination) or the repeated group (annual vaccination in all subsequent seasons with the nonadjuvanted trivalent split virus vaccine). The trivalent vaccine contained H1N1pdm09 as the A/ H1N1 component and A/H3N2 and B viruses. Twenty-five HCWs who provided peripheral blood mononuclear cells (PBMCs) and serum samples in 2012 and 2013 before the influenza season and vaccination were included in this study (Figure 1) .
The PBMCs were isolated using cell preparation tubes according to the manufacturer's instructions and cryopreserved at −150°C in 90% fetal calf serum/10% dimethyl sulphoxide until used. Sera were separated from clotted blood, aliquoted, and stored at −80°C until used.
Peptides and Virus
The influenza-specific CD4 and CD8 conserved peptide pools, which contained an optimal combination of HLA class I-and class II-restricted T-cell epitopes from viral internal proteins conserved among influenza A subtypes [15] , were chemically synthesized (Supplementary Tables 1 and  2 ). The split H1N1pdm09 antigen or egg-grown wild-type A/California/07/09(H1N1) virus were used to assess CD4 + or CD8 + T-cell responses, respectively.
Hemagglutination Inhibition Assay
Serum samples were used in duplicate with 0.7% turkey red blood cells and 8 hemagglutinating units of inactivated H1N1pdm09 antigen, as described previously [14] . The hemagglutination inhibition (HI) titer was determined as the reciprocal of the highest serum dilution causing 50% inhibition of hemagglutination. Negative titers (<10) were assigned a value of 5 for calculation purpose.
Fluorospot Assay
The influenza-specific IFN-γ/interleukin 2 (IL-2)-secreting T cells were measured by fluorospot assay following the manufacturer's instructions. Briefly, 400 000 PBMCs in Roswell Park Memorial Institute 1640 medium supplemented with 10% fetal bovine serum were stimulated with CD4 or CD8 conserved peptide pools (2 μg/mL), split H1N1pdm09 antigen (2.5 μg/mL), anti-CD3 T-cell activator (positive control), or medium alone (negative control) in duplicate overnight at 37°C with 5% carbon dioxide. Spot forming units (SFUs) were counted using a fluorescence reader fitted with color filters for FITC and Cy3. The average SFUs of duplicates were calculated. Background from negative controls was subtracted from stimulation responses.
Intracellular Cytokine Staining Assay
The PBMCs were stimulated in vitro with split H1N1pdm09 antigen (2.5 μg/mL), wild-type A/California/07/09(H1N1) virus (multiplicity of infection 5), phorbol-myristate acetate (25 ng/ mL)/ionomycin (250 ng/mL) (positive control), or lymphocyte medium (negative control) overnight at 37°C with 5% carbon dioxide and stained for T-helper 1 cytokines (IFN-γ/IL-2/tumor necrosis factor α [TNF-α]) as described [11] . Data were acquired on a BD LSRFortessa flow cytometer and analyzed in FlowJo, version 10. See Supplementary Table 3 and Figure 1 for the fluorochrome-conjugated antibodies and gating strategy used.
Statistical Analysis
The demographic and clinical characteristics, geometric mean HI titers, and T-cell SFUs between groups or within groups were examined by chi-square independence and nonparametric Mann-Whitney U or Wilcoxon signed-rank tests in SPSSStatistics version 24. The fold-changes of responses were log transformed, and the ranges were compared between groups. A general linear model was used to identify any correlation in the dataset. Comparisons of responses were controlled for subject variables and other characteristics using linear mixed-effect models in RStudio version 0.99.878. Graphs were plotted in Prism version 6. Analysis and presentation of cytokine profiles were performed in SPICE version 5.1 [16] . A P value < .05 was considered statistically significant.
RESULTS
Study Population
Twenty-five HCWs who had received an AS03-adjuvanted H1N1pdm09 vaccine in 2009 were enrolled in this study and categorized into either the single (n = 12) or the repeated group (n = 13) that received no further vaccination or received annual influenza vaccination during 2010-2013, respectively ( Figure  1 ). Blood samples were collected in 2012 and 2013 to allow multiple annual vaccinations in the repeated group. In 2013, 3 subjects from the single and 1 from the repeated group were excluded due to a change in their vaccination status from 2012. The mean age of participants was 42.3 (range = 30-64) years, with a female majority (n = 21/25) reflecting the demographics of the Norwegian healthcare sector. There were no significant differences in age, sex ratio, or other clinical characteristics between the 2 groups ( Table 1) .
Persistence of H1N1pdm09-Specific Antibodies and T Cells
The H1N1pdm09-specific antibody responses were assessed by the HI assay, the current standard serological test for detecting influenza antibody. No significant difference in antibody titers a P values were determined using Mann-Whitney U test for age and chi-square independence test for other variables.
b Pregnancy (single group), diabetes, and chronic respiratory diseases (repeated group).
was found between the single and the repeated groups measured at the start of the 2 consecutive influenza seasons ( Figure 2A ). Regardless of their vaccination history, the majority of HCWs had persistent HI titers above the protective threshold (HI titer ≥ 40): 78% (n = 7/9) in the single group and 83% (n = 10/12) in the repeated group ( Figure 2B ). Influenza-specific IFN-γ/IL-2-secreting T cells were measured in the fluorospot assay. In agreement with the persistent antibody titers, high frequencies of the H1N1pdm09-specific memory T cells were found in both groups over the 2 years ( Figure 3A-C) . However, the IFN-γ, IL-2, or IFN-γ IL-2-secreting H1N1pdm09-specific memory T cells were maintained in the repeated group for 1 year after the last vaccination. While a decline in frequencies of these T-cells secreting IFN-γ (P = .20), IL-2 (P = .04) and IFN-γ IL-2 (P = .03) was observed 3-4 years after a single vaccination.
Interestingly, using general linear models to identify any association between the HCW characteristics following the H1N1pdm09 vaccination and immune responses 3-4 years later in the 2 groups, we found a modest correlation between the adverse events reported after the 2009 pandemic vaccination and the strain-specific memory T-cell responses 3-4 years later in the single group (r 2 = 0.32; P = .001). A correlation between age and the magnitude of these responses was found following repeated vaccination (r 2 = 0.45; P = .01) (Supplementary Figure 2) . Older HCWs and those working on clinical wards in the repeated group tended to receive annual vaccination more frequently, even before 2009. The observed age effect may relate to the improved influenza-specific memory responses over time following repeated vaccination.
Maintenance of Cross-Reactive IFN-γ + CD4 + T-Cells after Repeated Vaccination
Recent work has demonstrated a protective role for CD4 + and CD8 + T cells recognizing internal viral proteins in limiting illness severity in humans [4] [5] [6] [7] . Here we explored the impact of repeated vaccination (3-4 years of annual seasonal vaccination) on the influenza-specific cross-reactive CD4 + and CD8 + T cells compared with natural exposure to influenza viruses (3-4 years after a single vaccination) in the fluorospot assay. Separate peptide pools of CD4 or CD8 epitopes (predominantly from nucleoprotein [NP] and matrix1 [M1] protein) highly conserved and prevalent across influenza A subtypes were used.
We found a significant decline in the frequencies of the cross-reactive IL-2 and IFN-γ IL-2-secreting CD4 + T cells after 1 year in both groups (P < .05) ( Figure 3E and 3F) . The frequencies of the cross-reactive IFN-γ + CD4 + T cells decreased significantly in the single group (P = .04) but were maintained in the repeated group for a year ( Figure 3D ). It is likely that repeated exposures to the same immunodominant viral NP and M1 antigens [17] , found in split virus seasonal vaccines [18, 19] , help maintain these responses.
Moreover, we observed stable cross-reactive IFN-γ + CD8 + T cells after 3-4 years of repeated vaccination ( Figure 3G ). A significant decrease in the IL-2 + CD8 + T cells was found (P = .004); however, the low frequencies of these cells (< 10 SFUs/million PBMCs, detection limit of 1) in both groups made it less robust ( Figure 3H ). Nevertheless, CD8 + T cells secreting IFN-γ, but not IL-2, have been found to correlate with protection [5, 6] . In contrast to the lack of maintenance of the CD4 + T-cells 3-4 years after a single vaccination, no decline in the frequencies of the cross-reactive CD8 + T cells was observed ( Figure 3G-I) . 
Maintenance of Central Memory and Effector Memory CD4 + T-Cells
Following Repeated Vaccination
We further investigated whether particular influenza-specific T-cell memory subsets were associated with the observed maintenance or decline of the cross-reactive CD4 + or CD8 + T cells. Subjects with the highest fold-decrease of CD4 + responses in the single group over the year and highest fold-decrease of IL-2 + CD8 + response for the repeated group while maintaining IFN-γ + CD4 + responses were selected (n = 5 per group). Using the intracellular cytokine staining (ICS) assay, we assessed cytokine responses of 4 memory subsets within CD4 + or CD8 + Figure 1) .
We found that IFN-γ and IL-2 were predominantly produced by the H1N1pdm09-specific CM and EM CD4 + subsets, regardless of the vaccination group ( Figure 4A and 4B) . In the single group, a trend of declining frequencies of IL-2−secreting CM (P = .07) and EM (P = .06) CD4 + T cells was observed ( Figure  5B and 5D), which may explain the decline in the cross-reactive CD4 + T-cell responses observed in the fluorospot assay. The fluorospot T-cell responses between groups and within groups between years were tested for statistical significance and controlled for subject variables and demographic and clinical factors (age, sex, working on clinical ward, seasonal influenza vaccination in 2009, previous seasonal influenza vaccination, underlying risk factors, and adverse events after the 2009 pandemic vaccination) using linear mixed-effect models. The fold-changes of responses were log transformed, and the ranges were compared between groups. *P < .05. **P < .01.
We found higher frequencies of the CM (P = .07) and EM (P = .04) IL-2 + CD4 + T cells in the repeated group compared with the single group in 2013. Consistent with our finding of the IFN-γ + CD4 + T-cell maintenance in the fluorospot assay, IFN-γ responses in the CM and EM CD4 + subsets were maintained in the repeated group for 1 year ( Figure 5A and 5C). The EM cells migrate to peripheral tissues and can immediately react with effector function upon antigen encounter. The high proportion of EM CD4 + subset following repeated vaccination is likely to provide influenza immunity. Furthermore the CM cells are long lived and can rapidly proliferate and differentiate into effector cells following antigen exposure [20] . It is tempting to speculate that the long-term persistence of T-cell responses following repeated antigen stimulation is by repetitive boosting of virus-specific CM T cells.
Unlike CD4 + T cells, the virus-specific IFN-γ + and IL-2 + CD8 + T cells were predominantly of the EM and EMRA subsets in both groups ( Figure 4C and 4D) . Because of large subject diversities, we did not observe any significant differences in the cytokine responses among memory CD8 + subsets in the 2 groups.
Enhanced Multifunctionality of CD4 + T-Cells after Repeated Vaccination
We explored the multifunctional cytokine-secreting (IFN-γ/ IL-2/TNF-α) quality of the influenza-specific T cells in a subset of participants (n = 5 per group). Seven distinct combinations of cytokine-secreting subsets were assessed; triple producer (IFN-γ + IL-2 + TNF-α + ), double producers (IFN-γ + IL-2 + ; IFN-γ + TNF-α + ; IL-2 + TNF-α + ) and single producers (IFN-γ + ; IL-2 + ; TNF-α + ).
We found a trend of declining proportions of multifunctional CD4 + T cells (secreting ≥ 2 cytokines) 3-4 years after a single vaccination (P = .06); these proportions were maintained following 3-4 repeated vaccinations, resulting in higher proportions of double producers in the repeated group (P = .01). Higher single producers were observed in the single group (P = .02) in 2013 ( Figure 6A , 6B, 6E, and 6F). Further analysis revealed a decline in the proportion of IL-2 + TNF-α + in the single group (P = .03) and an increase in IFN-γ + TNF-α + producers in the repeated group (P = .05) from 2012 to 2013 that contributed to the higher proportions of IL-2 + TNF-α + (P = .03) and IFN-γ + TNF-α + (P = .08) producers in the repeated group We observed no significant difference when comparing either the multifunctionality or each cytokine combination of CD8 + T cells. However, similar to CD4 + T cells, a trend of higher proportions of double producers was observed in the repeated group ( Figure 6I-P) .
DISCUSSION
It has been hypothesized that repeated annual influenza vaccination might adversely impact influenza-specific cross-reactive cellular immunity and consequently increase the risk of severe illness upon infection [3] . Remarkably, despite the use of influenza vaccination for >50 years, there are no data on the quality of memory T-cell responses following repeated vaccination in adults. This study, to our knowledge, is the first to investigate the magnitude, durability, and quality of CD4 + and CD8 + memory T-cell responses following repeated versus single vaccination and the longest follow-up of adults after the 2009 pandemic. Surprisingly and in contrast to our original hypothesis, we found that the strain-specific and cross-reactive IFN-γ + CD4 + and CD8 + T cells were maintained with more multifunctional cytokine-secreting T cells after multiple annual vaccinations. Furthermore, strain-specific antibodies persisted above the protective levels in repeatedly vaccinated adults. Our findings suggest there are potential immunological benefits from repeated annual vaccination and do not support the hypothesis that repeated vaccinations hamper cross-reactive T-cell immunity in adults.
A single influenza vaccination induces memory T cells cross-reactive against previously circulating and potentially pandemic strains [11, 21, 22] . Here, we show for the first time that repeated vaccination also maintains cross-reactive memory IFN-γ + CD4 + and CD8 + T cells. These findings suggest that healthy adults receiving multiple annual vaccinations would be protected against severe influenza illness in the event of vaccine , respectively. The memory T-cell subset responses between groups and within groups across time were tested for statistical significance and controlled for subject variables and demographic and clinical factors using linear mixed-effect models. The fold-changes of responses were log transformed, and the ranges were compared between groups. *P < .05. mismatch or emergence of a novel virus. This hypothesis might be tested by routinely collecting vaccination history alongside influenza surveillance data, which is used to estimate annual vaccine effectiveness. It also remains to be seen whether our findings extend to other high-risk groups. The indirect benefit on patients of vaccinating HCWs [23] and our findings showing limited adverse impact of repeated vaccinations on cross-reactive cellular immunity would advocate for continuing the annual vaccination policy in HCWs.
Influenza vaccination has been shown to elicit CD4 + responses [9, 10, 24] , correlating with neutralizing antibodies [12] . We extended these observations to characterize the functional quality of CD4 + T cells induced by repeated vaccination. Our multiparametric characterizations of the CD4 + population revealed that repeated vaccination maintained predominantly multi-cytokine-secreting CD4 + cells, whereas a skewing toward a single-cytokine-secreting T-cell population was observed in adults after a single vaccination. Multi-cytokine-secreting T cells have been shown to be functionally superior to single-cytokine producers in maintaining memory capacity [25, 26] and may be 1 explanation for the maintenance of cross-reactive IFN-γ + CD4 + T-cells after repeated vaccination. This qualitative difference in T-cell responses between our 2 groups reflects either the difference in vaccination history or the change in quality over time after antigen exposure. T-cell responses were analyzed 1 year after the last annual vaccination over 4 years in the repeated group compared with responses 3-4 years after a single vaccination in the single group.
Concerns were raised that preventing infection by annual vaccination would prevent induction of cross-reactive T cells [3] . One study demonstrated a hampering on the IFN-γ + CD8 + T cells in immunocompromised children who had received multiple annual vaccinations [13] . In our study of healthy adults who had received multiple annual vaccinations, stable IFN-γ + CD8 + T-cell frequencies were observed. Perhaps this is because of the age-related difference in the immune system. Memory T cells have been shown to rapidly increase in the first 2-3 decades of life before reaching homeostasis in adults [27] . Once established, the influenza-specific CD8 + T cells are long lived and measurable up to 10 years after infection [8] . It is likely that in children, annual vaccination may prevent necessary boosting of the CD8 + T-cell responses by natural infection, whereas in influenza-experienced adults, our findings suggest that a steady state of memory CD8 + T cells has already been reached, which may not require regular boosting by natural infection. We cannot exclude vaccination failures in our participants, which may have allowed infection-induced boosting of the T-cell response. However, the high titers of strain-specific antibodies and the absence of self-reported influenza illness or hospitalizations in our participants suggest this is unlikely.
Repeated vaccination with the same antigen has been reported to not significantly influence the antibody induction [28] [29] [30] . Our finding that a single administration of the adjuvanted H1N1pdm09 vaccine induced durable persistence of protective antibody responses without the boost from repeated vaccination is surprising. This is probably due to the AS03 adjuvant that was shown to increase vaccine immunogenicity [31] . This vaccine maintained not only persistently high antibody titers for up to 1 year [14, 29, 32, 33] , but also the quality of antibody responses [34] even in those who required revaccination to maintain their antibody titers [35] . Our finding extends this period of sustained antibody maintenance up to 4 years after vaccination and is the longest follow-up to date of adjuvanted vaccine-induced responses. Although we cannot exclude the possibility that this persistence may be due to regular exposure to circulating H1N1pdm09 strains through subclinical infection during the study, it is unlikely that all single-vaccinated HCWs were exposed to H1N1pdm09 in the preceding year. Our data also have implications for the use of AS03 adjuvant with other antibody-inducing vaccines such as those for malaria, respiratory syncytial virus, and Ebola.
The frequencies of the strain-specific and cross-reactive CD4 + T cells declined between 3-4 years after a single vaccination, which is consistent with our understanding of T-cell memory development in humans [36] . The high frequencies of H1N1pdm09-specific T cells after 3-4 years may be explained by the correlation between these T cells and the adverse events reported after H1N1pdm09 vaccination, which may reflect the strength of vaccine-induced immunity. Because we do not have T-cell data on earlier time points, we cannot distinguish between a continuous decline after vaccination or maintenance for 3 years after vaccination and a subsequent decline. Although this decrease was observed from peripheral blood, it is unlikely to be due to trafficking to the site of infection because blood was collected 2-3 months before the influenza epidemic and there was no self-reported influenza-like symptoms or illness.
We faced some caveats inherent in longitudinal cohort studies. Our strict inclusion criteria (not vaccinated in any subsequent season or vaccinated every year) designed to reduce the bias inherent in missing intervening vaccination history limited the sample size of this study to 25 subjects from 250 HCWs. We specifically chose HCWs because they are an important and stable population with good records of influenza vaccination and self-reported influenza-like illness. Although many of the comparisons between the 2 groups lost statistical significances after correcting for multiple-testing issue by Bonferroni method, we observed clear trends in the T-cell responses and therefore presented the results considering P value < .05 as significance. We believe our findings are valuable taking into account the difficulties to establish a cohort with reliable vaccination backgrounds. Also, the circulating T cells assessed in this study may not reflect local tissue-specific immune responses [37] . Our study was conducted after AS03 adjuvanted pandemic vaccination, and our findings of maintenance of T-cell immunity need to be confirmed after nonadjuvanted 2009 pandemic or annual seasonal vaccination. Further studies are required to evaluate both antibody and T-cell responses following repeated vaccination with nonadjuvanted vaccines, against other frequently changing seasonal vaccine strains, and in other high-risk groups recommended for annual vaccination.
Our study provides new insights into the impact of annual influenza vaccination on T-cell immunity with implications for vaccination policy and development. We found that the AS03-adjuvanted pandemic vaccine generated long-term durable antibodies and T cells after a single vaccination, which has significant implications for future vaccine design. Our findings reveal that repeated annual vaccination maintained strain-specific antibodies and T cells, importantly cross-reactive IFN-γ + CD4 + and CD8 + T cells. In conclusion, our study provides immunological evidence for continuing annual influenza vaccination policy in adults.
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